- Home
- CAN vs TECX Comparison
CAN vs TECX Comparison
Compare CAN & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CAN | TECX |
|---|---|---|
| Founded | 2013 | 2019 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 511.2M | 359.0M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CAN | TECX |
|---|---|---|
| Price | $0.67 | $20.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $3.56 | ★ $81.20 |
| AVG Volume (30 Days) | ★ 17.6M | 319.1K |
| Earning Date | 11-18-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $422,228,000.00 | N/A |
| Revenue This Year | $92.55 | N/A |
| Revenue Next Year | $41.93 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 83.87 | N/A |
| 52 Week Low | $0.53 | $13.70 |
| 52 Week High | $2.47 | $61.07 |
Technical Indicators
Market Signals| Indicator | CAN | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 32.69 | 55.30 |
| Support Level | $0.71 | $20.18 |
| Resistance Level | $0.89 | $22.00 |
| Average True Range (ATR) | 0.06 | 1.14 |
| MACD | -0.00 | 0.10 |
| Stochastic Oscillator | 2.13 | 72.45 |
Price Performance
Historical ComparisonAbout CAN Canaan Inc.
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.
About TECX Tectonic Therapeutic Inc.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.